Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016;14(1):17-27.
doi: 10.2174/1570159x13666150407225902.

From Clinical Application to Cognitive Enhancement: The Example of Methylphenidate

Affiliations
Review

From Clinical Application to Cognitive Enhancement: The Example of Methylphenidate

Francesco Paolo Busardò et al. Curr Neuropharmacol. 2016.

Abstract

Methylphenidate (MPD) is a central nervous system (CNS) stimulant, which belongs to the phenethylamine group and is mainly used in the treatment of attention deficit hyperactive disorder (ADHD). However, a growing number of young individuals misuse or abuse MPD to sustain attention, enhance intellectual capacity and increase memory. Recently, the use of MPD as a cognitive enhancement substance has received much attention and raised concerns in the literature and academic circles worldwide. The prescribing frequency of the drug has increased sharply as consequence of the more accurate diagnosis of the ADHD and the popularity of the drug itself due to its beneficial short-term effect. However, careful monitoring is required, because of possible abuse. In this review different aspects concerning the use of MPD have been approached. Data showing its abuse among college students are given, when the drug is prescribed short term beneficial effects and side effects are provided; moreover studies on animal-models suggesting long lasting negative effects on healthy brains are discussed. Finally, emphasis is given to the available formulations and pharmacology.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Methylphenidate chemical structure.
Fig. (2)
Fig. (2)
Adverse side effects of Methylphenidate reported by Aktepe et al. [87].

References

    1. Challman T.D., Lipsky J.J. Methylphenidate: its pharmacology and uses. Mayo Clin. Proc. 2000;75(7):711–721. doi: 10.1016/S0025-6196(11)64618-1. - DOI - PubMed
    1. Hamedi M., Mohammdi M., Ghaleiha A., Keshavarzi Z., Jafarnia M., Keramatfar R., Alikhani R., Ehyaii A., Akhondzadeh S. Bupropion in adults with Attention-Deficit/Hyperactivity Disorder: a randomized, double-blind study. Acta Med. Iran. 2014;52(9):675–680. - PubMed
    1. Mannuzza S., Klein R.G., Bessler A., Malloy P., LaPadula M. Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch. Gen. Psychiatry. 1993;50(7):76–565. doi: 10.1001/archpsyc.1993.01820190067007. - DOI - PubMed
    1. Morton W.A., Stockton G.G. Methylphenidate abuse and psychiatric side effects. Prim. Care Companion J. Clin. Psychiatry. 2000;2(5):159–164. doi: 10.4088/PCC.v02n0502. - DOI - PMC - PubMed
    1. Polanczyk G., de Lima M.S., Horta B.L., Biederman J., Rohde L.A. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am. J. Psychiatry. 2007;164(6):942–948. doi: 10.1176/ajp.2007.164.6.942. - DOI - PubMed

MeSH terms

LinkOut - more resources